These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9031902)

  • 1. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
    Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E; Mizokami M; Suzuki K; Ohba KI; Ohno T; Mizuno M; Iijima Y; Saito H; Nemoto A; Nukuta N
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
    Kakumu S; Aiyama T; Okumura A; Iwata K; Ishikawa T; Yoshioka K
    J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus genotype 1b and long-term response to interferon alpha monotherapy in children with chronic hepatitis C.
    Mozer-Lisewska I; Słuzewski W; Ali Youseif K; Figlerowicz M; Kowala-Piaskowska A
    Eur J Pediatr; 2003 Nov; 162(11):755-9. PubMed ID: 12937972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha interferon treatment in chronic hepatitis C.
    Idéo G; Bellobuono A; Mondazzi L; Tempini S; Bellati G; Idéo GM; Silini E
    Clin Exp Rheumatol; 1995; 13 Suppl 13():S167-73. PubMed ID: 8730501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4.
    el-Zayadi A; Simmonds P; Dabbous H; Prescott L; Selim O; Ahdy A
    J Viral Hepat; 1996 Sep; 3(5):261-4. PubMed ID: 8914006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
    Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
    Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.